Amwise focuses on advanced precision medicine in oncology, striving to shape a better world for cancer patients. We provide healthcare professionals and patients with quantitative data to help determine the appropriate approaches in treatment. We expect patients can receive highest heal possibility with minimum side effects by avoiding unnecessary treatments.

Amwise successfully developed advanced precision diagnostics based on Asian genes. Current technology can help breast cancer patients to evaluate the necessity of chemo therapy and radiation therapy. Amwise is also developing prognosis testing for colorectal cancer. Amwise is also developing a chemo predictor to apply in Pancreatic Cancer and utilizing and integrating the most cutting-edge technology to lead the sector into a new era.

Investment year:
Sean Huang
Related News